PMS-VALACYCLOVIR 1000 MG
VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE) : 1000 MG · DIN 02381230 · PHARMASCIENCE INC
Health Canada status: MARKETED
What is PMS-VALACYCLOVIR?
PMS-VALACYCLOVIR 1000 MG contains VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE) : 1000 MG. It is listed in the Health Canada Drug Product Database under DIN 02381230, held by PHARMASCIENCE INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 13-Mar-2012. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PMS-VALACYCLOVIR used for?
Treatment of herpes zoster (shingles); treatment/suppression of genital herpes; reduction of transmission of genital herpes; treatment of cold sores (herpes labialis).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02381230 |
|---|---|
| Brand name | PMS-VALACYCLOVIR |
| Generic / active ingredient | VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE) : 1000 MG |
| Manufacturer | PHARMASCIENCE INC |
| Strength | 1000 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | J05AB11 VALACICLOVIR |
| AHFS class | 08:18.32 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 13-Mar-2012 |
| Original market date | 2012-03-13 00:00:00 |
How is it administered?
Herpes Zoster: 1000 mg 3x daily for 7 days. Genital Herpes (Initial): 1000 mg 2x daily for 10 days. Cold Sores: 2000 mg 2x daily for 1 day. Adjust dose for renal impairment.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (standard section 11 mentioned in TOC but text cuts off). Typically 15-30°C.
How is it supplied?
500 mg: Bottles of 100 tablets. 1000 mg: Bottles of 100 tablets and blister packs of 21 tablets.
Contraindications
Known hypersensitivity or intolerance to valacyclovir, acyclovir, or any component of the formulation.
Warnings and precautions
Risk of TTP/HUS in immunocompromised patients. Ensure adequate hydration to prevent renal failure. CNS adverse reactions possible, especially in elderly or renally impaired. Risk of DRESS.
What can be used instead?
Other Canadian products sharing ATC code J05AB11 VALACICLOVIR. 22 of 36 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-VALACYCLOVIR | 500 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02500582 |
| APO-VALACYCLOVIR | 1000 MG | TABLET | APOTEX INC | MARKETED | DIN 02354705 |
| APO-VALACYCLOVIR | 500 MG | TABLET | APOTEX INC | MARKETED | DIN 02295822 |
| AURO-VALACYCLOVIR | 1000 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02405059 |
| AURO-VALACYCLOVIR | 500 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02405040 |
| JAMP VALACYCLOVIR | 1000 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02558858 |
| JAMP VALACYCLOVIR | 500 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02440598 |
| MYLAN-VALACYCLOVIR | 1000 MG | TABLET | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02351560 |
| MYLAN-VALACYCLOVIR | 500 MG | TABLET | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02351579 |
| NB-VALACYCLOVIR | 500 MG | TABLET | NB PHARMA INC. | MARKETED | DIN 02558130 |
Who else supplies VALACICLOVIR worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. VALACICLOVIR appears in 387 registered pack listings across 13 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.